The identified protein signatures offer promising biomarkers for risk prediction, enabling early identification of high-risk individuals with PRISm and informing targeted preventive strategies for cardiometabolic complications.
He et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: